Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
167%(5 trials)
Terminated
2(40%)

Phase Distribution

Ph phase_3
2
40%
Ph phase_4
2
40%
Ph phase_1
1
20%

Phase Distribution

1

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 3Large-scale testing
2(40.0%)
Phase 4Post-market surveillance
2(40.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Terminated(2)

Detailed Status

Completed3
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
60.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (20.0%)
Phase 32 (40.0%)
Phase 42 (40.0%)

Trials by Status

completed360%
terminated240%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_3

Natalizumab Re-Initiation of Dosing

NCT00306592
completedphase_4

A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients

NCT00871780
completedphase_4

The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis

NCT00536120
terminatedphase_1

Study of Natalizumab in Relapsed/Refractory Multiple Myeloma

NCT00675428
terminatedphase_3

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis

NCT01058005

Clinical Trials (5)

Showing 5 of 5 trials
NCT00306592Phase 3

Natalizumab Re-Initiation of Dosing

Completed
NCT00871780Phase 4

A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients

Completed
NCT00536120Phase 4

The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis

Completed
NCT00675428Phase 1

Study of Natalizumab in Relapsed/Refractory Multiple Myeloma

Terminated
NCT01058005Phase 3

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5